Tong Sun, MD, PhD
Assistant Professor of PathologyCards
About
Titles
Assistant Professor of Pathology
Biography
Dr. Sun received her medical degree from Peking University Health Science center and her Ph.D. in molecular oncology from Peking Union Medical College. She joined in Gelb Genitourinary translation research center as a research fellow in Dana-Farber Cancer Institute/Harvard Medical School, where she was later promoted as a research scientist and mainly focused on genetic markers and post-translational regulation mechanism involved in castration resist prostate cancer. She completed residency training in Anatomic and Clinical Pathology at University of Massachusetts Medical School and a Cytopathology Fellowship at the Massachusetts General Hospital. She joined Yale Pathology Staff in 2020. Dr. Sun loves all aspects of general surgical pathology and cytopathology, but has research interests particularly in translational and molecular studies involving gynecological and gentiourinary pathology. She earned Warren R. Lang, MD Resident Physician Award and Journal of American Society of Cytopathology Physician-in-training Award for investigating utility of next-generation sequencing in urine cytology specimens. She has published more than 50 peer-reviewed publications including 5 book chapters and reviews. She serves as a reviewer for 25 scientific journals.
Appointments
Pathology
Assistant ProfessorPrimary
Other Departments & Organizations
- Gynecological Pathology
- Pathology
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Cytopathology Fellow
- Massachusetts General Hospital (2020)
- Resident Physcian
- University of Massachusetts (2019)
- Research Scientist
- Dana-Farber Cancer Institute (2015)
- MD
- Peking University Health Science Center (2012)
- Postdoctoral Research Fellow
- Dana-Farber Cancer Institute (2011)
- PhD
- Peking Union Medical College (2007)
- MD
- Peking University (2002)
Research
Publications
2025
The Evolving Molecular Landscape of Uterine Mesenchymal Tumors: Diagnostic and Therapeutic Implications
Sun T. The Evolving Molecular Landscape of Uterine Mesenchymal Tumors: Diagnostic and Therapeutic Implications. Cancers 2025, 17: 4012. PMID: 41463261, PMCID: PMC12730577, DOI: 10.3390/cancers17244012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsUterine mesenchymal tumorsInflammatory myofibroblastic tumorEndometrial stromal tumorsInternal tandem duplicationMesenchymal tumorsOvarian sex cord tumorsPerivascular epithelioid cell tumorMolecular landscapeSex cord tumorsRecurrent genetic alterationsSmooth muscle tumorsEpithelioid cell tumorHigh-grade tumorsDiagnostically challenging groupBCOR internal tandem duplicationMyofibroblastic tumorCord tumorsMuscle tumorsUterine tumorsStromal tumorsRare entityCell tumorsClinically significant neoplasmsATRX mutationsCDK4/6 inhibitionEndometrial carcinomas – Challenges and updates on selected topics
Buza N, Sun T, Hui P. Endometrial carcinomas – Challenges and updates on selected topics. Human Pathology 2025, 169: 106016. PMID: 41389900, DOI: 10.1016/j.humpath.2025.106016.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPrimary endometrial squamous cell carcinomaMinimal uterine serous carcinomaMesonephric-like adenocarcinomaEndometrial serous carcinomaSerous carcinomaEndometrial carcinomaEndometrioid carcinomaEndometrial squamous cell carcinomaVariant of endometrioid carcinomaSerous endometrial intraepithelial carcinomaHigh-grade endometrial carcinomasHeterogeneous group of tumorsSubtypes of endometrial carcinomaEndometrial cancer deathsHyalinized endometrioid carcinomaMinimal tumour volumeSuperficial serous carcinomaEndometrial intraepithelial carcinomaUterine serous carcinomaHeterogeneous groupAssociated with p53 abnormalitiesGroup of tumorsSquamous cell carcinomaExtrauterine spreadIntraepithelial carcinomaPrognostic significance of pelvic washing cytology in early stage endometrial cancer: A 10‐year matched cohort analysis from a large single institute
Wang M, Abi‐Raad R, Adeniran A, Krishnamurti U, Buza N, Hui P, Cai G, Sun T. Prognostic significance of pelvic washing cytology in early stage endometrial cancer: A 10‐year matched cohort analysis from a large single institute. Cancer Cytopathology 2025, 133: e70057. PMID: 41159755, DOI: 10.1002/cncy.70057.Peer-Reviewed Original ResearchConceptsEarly stage endometrial cancerPW cytologyStage endometrial cancerPelvic washingsAccurate risk stratificationEndometrial cancerPrognostic significancePrognostic impactIndependent predictorsInternational Federation of Gynecology and Obstetrics (FIGO) criteriaStage I/II endometrial cancerAccurate risk stratification of patientsIndependent adverse prognostic factorAssociated with significantly worse disease-free survivalRisk stratification of patientsPelvic washing cytologyRetrospective case-control cohortsMultivariate logistic regression analysisEndometrial cancer stagingAdverse prognostic factorDisease-free survivalInternational FederationTumor histologic subtypeII endometrial cancerEarly stage diseaseFumarate Hydratase-deficient Uterine Smooth Muscle Tumors: A 6-Year Prospective Analysis of Morphology-based Screening and Patient Outcomes.
Sun T, Niu N, Healy C, Abdelal H, Wang M, Hui P, Buza N. Fumarate Hydratase-deficient Uterine Smooth Muscle Tumors: A 6-Year Prospective Analysis of Morphology-based Screening and Patient Outcomes. International Journal Of Gynecological Pathology 2025 PMID: 40991420, DOI: 10.1097/pgp.0000000000001134.Peer-Reviewed Original ResearchUterine smooth muscle tumorsSmooth muscle tumorsFH deficiencyRenal cell carcinomaMuscle tumorsUterine leiomyomaCell carcinomaFumarate hydratasePathogenic variantsEarly-onset uterine leiomyomasGenetic counselingPapillary renal cell carcinomaProspective analysisFH-deficient leiomyomasGermline fumarate hydrataseSeventy-one tumorsAbnormal vaginal bleedingMedian patient ageHereditary cancer-related genesGermline pathogenic mutationsAutosomal dominant disorderFH-deficient tumorsCancer-related genesFH immunohistochemistryPelvic painHigh-grade Serous Carcinomas Identified in Cervical Biopsies: A Clinicopathologic Study Supporting the Exclusion of Cervical Serous Carcinoma from World Health Organization Classification
Maruthi V, Sun T. High-grade Serous Carcinomas Identified in Cervical Biopsies: A Clinicopathologic Study Supporting the Exclusion of Cervical Serous Carcinoma from World Health Organization Classification. Journal Of Clinical And Translational Pathology 2025, 000: 000-000. DOI: 10.14218/jctp.2025.00023.Peer-Reviewed Original ResearchHuman papillomavirus genotype distribution and its correlation with intraepithelial neoplasia, vaccination, and ethnicity
Abi-Raad R, Sun T, Krishnamurti U. Human papillomavirus genotype distribution and its correlation with intraepithelial neoplasia, vaccination, and ethnicity. Journal Of The American Society Of Cytopathology 2025, 14: 273-278. PMID: 40307088, DOI: 10.1016/j.jasc.2025.03.006.Peer-Reviewed Original ResearchConceptsHigh-risk human papillomavirusNon-16/18ASC-HHPV genotypesIntraepithelial neoplasiaCases of high-grade squamous intraepithelial lesionCervical cancerPositive high-risk HPVHigh-risk HPVHigh-risk human papillomavirus genotypesHuman papillomavirus genotype distributionNon-16/18 HPV genotypesPrevalence of HPV genotypesHigh-risk human papillomavirus typesHigh-grade intraepithelial neoplasiaIntroduction of HPV vaccinationIncidence of cervical cancerAtypical squamous cellsSquamous intraepithelial lesionsHigh-grade lesionsHSIL patientsNonvaccinated womenIntraepithelial lesionsVaccinated womenSquamous cellsComprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas
Antony V, Sun T, Dolezal D, Cai G. Comprehensive Molecular Profiling of Metastatic Pancreatic Adenocarcinomas. Cancers 2025, 17: 335. PMID: 39941707, PMCID: PMC11815932, DOI: 10.3390/cancers17030335.Peer-Reviewed Original ResearchMetastatic pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaPrimary pancreatic ductal adenocarcinomaMolecular profilingGene mutationsGene copy number alterationsAdvanced-stage pancreatic cancerInsufficient tumor cellsOncomine Comprehensive AssayRate of TP53Copy number alterationsMetastatic diseasePDAC casesPIK3CA mutationsPancreatic cancerPoor prognosisTreatment optionsDuctal adenocarcinomaTumor cellsTumor progressionMolecular alterationsStudy cohortMolecular testingComprehensive assayTherapeutic target
2024
Reevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience
Takeda K, Cai G, Adeniran A, Sun T. Reevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience. American Journal Of Clinical Pathology 2024, 162: aqae077. PMID: 38916141, DOI: 10.1093/ajcp/aqae077.Peer-Reviewed Original ResearchCystic fluid cytologyFine-needle aspirationFluid cytologyAmerican College of Obstetricians and Gynecologists guidelinesSingle-institution cohortRate of malignancySurgical pathology diagnosisFNA casesGynecologists guidelinesCytological diagnosisFNA cytologyPathological diagnosisPatient demographicsInstitutional experienceSurgical pathologyOvarian cyst fluidClinical circumstancesAmerican CollegeCytologyRadiological informationMalignancyGold standardCyst fluidModerate sensitivityPotential safety concernsDiandric triploid partial mole versus digynic nonmolar triploidy: is morphological assessment sufficient for the diagnostic distinction?
Nagy A, Niu N, Sun T, Buza N, Hui P. Diandric triploid partial mole versus digynic nonmolar triploidy: is morphological assessment sufficient for the diagnostic distinction? Histopathology 2024, 85: 879-888. PMID: 39031756, DOI: 10.1111/his.15247.Peer-Reviewed Original ResearchPositive predictive valueTriploid gestationsPartial moleTrophoblastic hyperplasiaVillous sizeCistern formationHistological parametersPostmolar gestational trophoblastic neoplasiaTriploid partial molesGenotype-phenotype correlation studiesGestational trophoblastic neoplasiaPartial Hydatidiform MoleModerate interobserver agreementVillous populationsTrophoblastic neoplasiaGestational weeksHydatidiform MoleClinical presentationPatient ageDigynic triploidyAbnormal histologyInterobserver agreementGestationSyncytiotrophoblastHistological assessmentTargetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations
Manrai P, McHenry A, Sun T, Santin A, Ratner E, Lin D, Elvin J, Hui P, Buza N. Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations. International Journal Of Gynecological Pathology 2024, 44: 144-154. PMID: 38914011, DOI: 10.1097/pgp.0000000000001050.Peer-Reviewed Original ResearchEndometrial carcinomaGynecologic malignanciesTyrosine kinase domainHER2-mutated non-small cell lung cancerTargeted anti-HER2 therapyNon-small cell lung cancerHigh-grade endometrioid adenocarcinomasFam-trastuzumab deruxtecanOvarian mucinous adenocarcinomaAnti-HER2 therapyAnti-HER2 drugsHER2 3+US Food and Drug AdministrationCell lung cancerEndometrial serous carcinomaSolid tumor typesStandard treatment recommendationsFood and Drug AdministrationFluorescence in situ hybridizationGynecological cancer typesEndometrial primaryMullerian originSerous carcinomaHER2 IHCEndometrioid adenocarcinoma
News
News
- March 17, 2026
Yale Pathology Will Have Strong Presence at USCAP 2026
- May 06, 2025
Beverly Levy Walk and Block Party Highlights Value of Cancer Research
- May 06, 2025
Yale ENT, Yale Pathology Team Provide Cancer Screenings at Beverly Levy Walk and Block Party
- November 07, 2023
Yale Diagnostic Pathology Annual CME Review held in NYC